Merck & Company (MRK) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Merck & Company (MRK)

147.18

-0.87 (0.59%)

as of Nov 11, 2026, 9:00:00 pm Market Closed.

312 watching

DON'T BUY

A cockroach company with one problem after another coming out of the woodwork.

DON'T BUY

In 2002, 2003 and early 2004 the chart looked like it was going to hold, but then collapsed. A broken down stock. Usually takes a significant amount of time for the news to be absorbed.

DON'T BUY

More aggressive than what they would want. A number of outstanding issues regarding litigation would keep the top executives eyes off running the business. Prefers Pfizer.

DON'T BUY

Market is pricing in $20/25 million for class action law suits, but it could be more. Would need a tremendous amount of earnings growth to reach what people are expecting and this is unlikeley. High dividend yield. No longer a safe story.

PAST TOP PICK

(A Top Pick July 12/04. Down 40%.) Sold out before the big drop.

BUY

Pharmaceuticals are cheaper than he has ever seen them. Cheap. Trading at low multiples.

DON'T BUY

Took a tremendous hit with their withdrawal of Vioxx. Buying it now would be bottom fishing. A lot of issues going on in the pharma sector now. Weak pipeline.

DON'T BUY

Has declined because of a recall of one of their drugs. Will probably have a bounce.

PAST TOP PICK

(A Top Pick Apr 28/04. Down 4%.) Had bought for the wrong reasons. Bought at the top of a cycle as a defensive play. Don't buy.

TOP PICK

Dividend yield is very attractive. You pay very little for the upside.

TOP PICK

Yield is over 3%. Trading around 15 X next year's earnings.

TOP PICK

This late in the cycle, look for stocks that are large, overlooked and underowned. Had a low in 2002 and a higher low at the end of 2003 in a downtrend, still expects to see money going to this group.

WEAK BUY

Have more patent issues than the majority of the big pharmas. Not a lot of catalysts. If you are a real long-term, patient investor, not a bad buy.

BUY

Big pharma stocks should do well in this market. Historically, they do well when rates start to move up.

DON'T BUY

Still under a major downtrend line. Trying to find a base.

Showing 256 to 270 of 314 entries

Most Recent Experts

Jim Cramer - Mad Money

CNBC

John Stephenson

Stephenson & Company Capital Management

Christine Poole

Davis Rea

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Dan Rohinton

iA Global Asset Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Merck & Company (MRK)